Qianhai Health Holdings Ltd. (0911) AI Stock Analysis

• Market Cap: HK$37.28M
• Dividend Yield: N/A
• Average Volume (3M): 43.31K
• Price to Earnings (P/E): 28.6
• Beta (1Y): 0.79
• Revenue Growth: -45.94%
• EPS Growth: N/A
• Country: HK
• Employees: 14
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 169,445,000
• 10 Day Avg. Volume: 22,000
• 30 Day Avg. Volume: 43,306
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ―

Qianhai Health Holdings Ltd. exhibits some financial improvements with a return to profitability and strong balance sheet, but significant revenue volatility and cash flow concerns are major risks. Technical indicators signal a bearish trend, while the high P/E ratio suggests the stock may be overvalued. Overall, the stock faces challenges that could impact future performance.

Qianhai Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Qianhai Health Holdings Ltd. (0911) is a Hong Kong-based investment holding company primarily engaged in the health industry. The company operates through various segments, including health and wellness products, health management services, and the sale of healthcare-related products. It aims to leverage its expertise in health management to provide innovative and effective solutions to its customers.

How the Company Makes Money

Qianhai Health Holdings Ltd. generates revenue through the sale of health and wellness products, which may include nutritional supplements, personal care items, and other health-related goods. Additionally, the company offers health management services, which could encompass health assessments, consultancy, and personalized health plans. Revenue is also derived from strategic partnerships and collaborations that enhance its product offerings and expand its market reach. The company's earnings are influenced by its ability to effectively market its products and services, as well as its capacity to maintain and grow partnerships that provide access to broader consumer bases.

Qianhai Health Holdings Ltd. Financial Statement Overview

Summary

Qianhai Health Holdings Ltd. shows signs of financial improvement with a return to profitability in 2024. However, the company's significant revenue fluctuations and cash flow challenges highlight potential risks. While the balance sheet remains strong with low debt levels, the company must address its cash flow issues to ensure sustainable growth.

Income Statement

The company's revenue has shown significant volatility with a notable decline from 2022 to 2023. Despite this, the gross profit margin improved to 5.71% in 2024 from a negative margin in 2023. Net profit margins have improved from negative to a marginally positive 0.25% in 2024, indicating a turnaround. However, the negative revenue growth rate and fluctuating EBIT and EBITDA margins signal instability and potential risk.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 94.67% in 2024, suggesting financial stability and low leverage risk with a debt-to-equity ratio of only 0.0027. However, the overall decrease in total assets over the years could be a concern for future growth potential.

Cash Flow

The cash flow situation is concerning, as operating and free cash flows were zero in 2024, indicating potential liquidity issues. The company has previously experienced negative cash flows, which could affect its ability to invest and grow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
519.70M	961.29M	1.96B	283.40M	760.72M
	Gross Profit
29.67M	-35.60M	76.48M	16.04M	45.13M
	EBIT
13.92M	-52.70M	-256.79M	-4.64M	4.80M
	EBITDA
15.64M	-50.23M	-231.24M	2.06M	5.63M
	Net Income Common Stockholders
1.31M	-52.70M	-211.75M	1.48M	-6.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.51M	19.52M	1.64M	2.47M	16.36M
	Total Assets
407.31M	478.12M	534.43M	738.63M	735.47M
	Total Debt
1.03M	487.00K	1.19M	7.83M	24.07M
	Net Debt
-22.22M	-19.04M	-455.00K	5.36M	7.70M
	Total Liabilities
21.74M	94.00M	97.73M	68.09M	62.28M
	Stockholders Equity
385.57M	384.11M	436.70M	670.53M	673.19M
Cash Flow		Free Cash Flow
0.00	857.00K	-5.26M	-44.19M	-70.90M
	Operating Cash Flow
0.00	857.00K	-5.26M	-44.18M	-70.89M
	Investing Cash Flow
0.00	17.77M	12.34M	46.84M	122.43M
	Financing Cash Flow
0.00	-743.00K	-7.91M	-16.56M	-55.19M

Qianhai Health Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.22, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.01 is Neutral, neither overbought nor oversold. The STOCH value of 58.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0911.

Qianhai Health Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1111	79 Outperform		2.60		―	―	―
6666	58 Neutral	HK$8.11B	7.52	2935.68%	―	0.27%	-35.07%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
2222	46 Neutral	HK$410.89M	1.33	-3.70%	―	-0.07%	-148.33%
0911	44 Neutral	HK$37.28M	28.57	0.34%	―	-45.94%	―

Qianhai Health Holdings Ltd. Corporate Events

Qianhai Health Holdings Schedules Board Meeting for Financial Results and Dividend Consideration

Qianhai Health Holdings Ltd. announced that its Board of Directors will meet on March 24, 2025, to consider and approve the company’s audited financial results for the year ending December 31, 2024. The board will also discuss the potential recommendation for a final dividend payment, which could impact shareholder returns and reflect the company’s financial health.